Takeshi Kumada

99PUBLICATIONS
165CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (99)

|Aug 18, 2026
Response to the Letter Regarding "Methodological Considerations in Real-World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma".

|Aug 07, 2026
Response to the Letter Regarding "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial".

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|May 22, 2026
Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline-A Step Towards Functional Cure or a Marginal Margin? Authors' Reply.

Pageof 17

Frequent Collaborators

80 joint publications

Hidenori Toyoda

71 joint publications

Toshifumi Tada

50 joint publications

Atsushi Hiraoka

44 joint publications

Takeshi Hatanaka